PTC takes a chance on Sangamo’s Fabry disease gene therapy
Source ↗
👁 2
💬 0
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.
Comments (0)